0.2362
Glycomimetics Inc stock is traded at $0.2362, with a volume of 672.06K.
It is down -9.33% in the last 24 hours and up +8.25% over the past month.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
See More
Previous Close:
$0.2605
Open:
$0.2567
24h Volume:
672.06K
Relative Volume:
0.56
Market Cap:
$14.61M
Revenue:
$1.16M
Net Income/Loss:
$-39.74M
P/E Ratio:
-0.381
EPS:
-0.62
Net Cash Flow:
$-35.02M
1W Performance:
+4.28%
1M Performance:
+8.25%
6M Performance:
-51.80%
1Y Performance:
-84.76%
Glycomimetics Inc Stock (GLYC) Company Profile
Name
Glycomimetics Inc
Sector
Industry
Phone
240-243-1201
Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare GLYC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GLYC
Glycomimetics Inc
|
0.2362 | 14.61M | 1.16M | -39.74M | -35.02M | -0.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
Dec-22-23 | Initiated | CapitalOne | Overweight |
Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
Nov-14-19 | Initiated | ROTH Capital | Buy |
Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
Apr-12-19 | Initiated | Piper Jaffray | Overweight |
Dec-18-18 | Initiated | H.C. Wainwright | Buy |
Jul-26-16 | Initiated | SunTrust | Buy |
Mar-17-15 | Reiterated | Stifel | Buy |
View All
Glycomimetics Inc Stock (GLYC) Latest News
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
GlycoMimetics, Inc. (GLYC) Stock Report: Analyst Ratings Signal Potential in Biotech Space - DirectorsTalk Interviews
Press Release Distribution & PR Platform - ACCESS Newswire
A Look at GlycoMimetics Inc (GLYC) Shares in the Recent Past Indicates Growth - Sete News
GLYC Shares Experience Surge in Value - knoxdaily.com
GlycoMimetics (NASDAQ:GLYC) Stock Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc (GLYC) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Understanding GLYC stock ratios for better investment decisions - uspostnews.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Wellington Management Group LLP Makes New Investment in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD - MarketScreener
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
Form 425 GLYCOMIMETICS INC Filed by: GLYCOMIMETICS INC - StreetInsider
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow
GLYCOMIMETICS Earnings Preview: Recent $GLYC Insider Trading, Hedge Fund Activity, and More - Nasdaq
Cantor Fitzgerald Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock By Investing.com - Investing.com Australia
Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation - MSN
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock - Investing.com India
Cantor Fitzgerald Initiates GlycoMimetics at Overweight -March 21, 2025 at 07:18 am EDT - Marketscreener.com
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update - Defense World
StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. to Host Earnings Call - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - The Malaysian Reserve
GlycoMimetics, Inc. Announces Board Resignations -February 25, 2025 at 05:00 pm EST - Marketscreener.com
GlycoMimetics Says Following Termination, Co Will Not Have Any Material Financial Or Other Obligations Under Agreement - TradingView
GlycoMimetics ends key agreement; board members, executives depart By Investing.com - Investing.com South Africa
GlycoMimetics ends key agreement; board members, executives depart - Investing.com
GlycoMimetics Faces Leadership Changes Amid Board Resignations - TipRanks
US Penny Stocks To Watch In February 2025 - Yahoo Finance
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week - NewsBreak
GlycoMimetics adjusts merger terms with Crescent Biopharma - MSN
GlycoMimetics And GENFIT Announce Significant Agreement Amendments - Evrim Ağacı
GlycoMimetics adjusts merger terms with Crescent Biopharma By Investing.com - Investing.com UK
GLYCOMIMETICS INC SEC 10-K Report - TradingView
Glycomimetics, Inc. Announces Cessation of Brian Hahn as Chief Financial Officer, No Later Than March 31, 2025 - Marketscreener.com
Glycomimetics Inc Stock (GLYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):